Arnold M. Schwartz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Arnold M. Schwartz has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Donald E. Henson
Affiliations of authors: Cancer Institute (DEH, AP) and Department of Pathology (AMS) , and Department of Surgery (AMS) , George Washington University , Washington, DC
3 shared publicationsM. Katayoon Rezaei
The George Washington University Medical Center, Department of Pathology, Washington, DC
3 shared publications- Donald Earl Henson
The George Washington University Cancer Institute
2 shared publications - Alexander H. Cho
Pulmonary/Critical Care Department, Washington University, Washington, DC
1 shared publication Amy Tilara
1 shared publicationAnkita Patel
Affiliations of authors: Cancer Institute (DEH, AP) and Department of Pathology (AMS) , and Department of Surgery (AMS) , George Washington University , Washington, DC
1 shared publication
Latest Publications
- 1 January 2016
- Published by Elsevier in Clinical Imaging
- Vol. 40 (1) , 177-179
The role of PET scan in monitoring the progression of fibrosing mediastinitis
- 1 January 2016
- Published by Elsevier in Clinical Imaging
- Vol. 40 (1) , 177-179
The role of PET scan in monitoring the progression of fibrosing mediastinitis
- 15 May 2014
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 106 (5)
Circulating Tumor Cells: What Goes Around, Comes Around
- 15 May 2014
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 106 (5)
Circulating Tumor Cells: What Goes Around, Comes Around
- 11 December 2013
- Published by Wiley in Journal of Surgical Oncology
- Vol. 109 (5) , 391-394
The clinical implications of integrating additional prognostic factors into the TNM
- 11 December 2013
- Published by Wiley in Journal of Surgical Oncology
- Vol. 109 (5) , 391-394
The clinical implications of integrating additional prognostic factors into the TNM
- 20 November 2013
- Published by Georg Thieme Verlag KG in Seminars in Respiratory and Critical Care Medicine
- Vol. 34 (06) , 770-786
Surgical Pathology of Lung Cancer
The diagnosis, treatment, and management of lung tumors represent a complex set of decision algorithms and require the cooperation and interaction of a team of experts and support systems. The surgical pathologist, an early, important member of the diagnostic team, uses clinical and radiological evidence to differentiate benign from malignant tumors and renders a unique diagnosis that provides both prognostic and treatment information. Using routine histopathologic criteria, histochemical and immunohistochemical stains, and molecular and genetic testing, surgical pathologists and cytopathologists may distinguish between small cell and other bronchogenic carcinomas, separate adenocarcinomas from squamous cell carcinomas, differentiate between pleural carcinomas and diffuse malignant mesotheliomas, and discriminate among the varieties of neuroendocrine carcinomas. Among adenocarcinomas, the pathological examination stratifies those tumors with absent or minimal central invasive cores that have an excellent prognosis from the more common adenocarcinomas with larger invasive components. These distinctions are necessary based on differences in tumor biology, response to therapy, and prognosis for these different histological types. Histopathologic analysis should attempt to provide a precise diagnosis and limit the usage of the term non–small cell carcinoma. The team approach also enables the optimal use of tumor tissue for diagnostic purposes as well as molecular genetic testing and the discovery of targetable sites for therapeutic management. Though low-stage tumors tend to be initially treated with surgical resection, more advanced stages will be approached with limited tissue acquisition, necessitating a strategy for best practices of scarce tissue resources. The awareness of diagnostic modalities and tissue handling by all members of the team ensures the best patient-centered care.
- 20 November 2013
- Published by Georg Thieme Verlag KG in Seminars in Respiratory and Critical Care Medicine
- Vol. 34 (06) , 770-786
Surgical Pathology of Lung Cancer
The diagnosis, treatment, and management of lung tumors represent a complex set of decision algorithms and require the cooperation and interaction of a team of experts and support systems. The surgical pathologist, an early, important member of the diagnostic team, uses clinical and radiological evidence to differentiate benign from malignant tumors and renders a unique diagnosis that provides both prognostic and treatment information. Using routine histopathologic criteria, histochemical and immunohistochemical stains, and molecular and genetic testing, surgical pathologists and cytopathologists may distinguish between small cell and other bronchogenic carcinomas, separate adenocarcinomas from squamous cell carcinomas, differentiate between pleural carcinomas and diffuse malignant mesotheliomas, and discriminate among the varieties of neuroendocrine carcinomas. Among adenocarcinomas, the pathological examination stratifies those tumors with absent or minimal central invasive cores that have an excellent prognosis from the more common adenocarcinomas with larger invasive components. These distinctions are necessary based on differences in tumor biology, response to therapy, and prognosis for these different histological types. Histopathologic analysis should attempt to provide a precise diagnosis and limit the usage of the term non–small cell carcinoma. The team approach also enables the optimal use of tumor tissue for diagnostic purposes as well as molecular genetic testing and the discovery of targetable sites for therapeutic management. Though low-stage tumors tend to be initially treated with surgical resection, more advanced stages will be approached with limited tissue acquisition, necessitating a strategy for best practices of scarce tissue resources. The awareness of diagnostic modalities and tissue handling by all members of the team ensures the best patient-centered care.
- Open Access
- 2 May 2013
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 105 (11) , 759-761
A Primary Approach to Cancers of Unknown Primary
Most solid tumors are diagnosed in their organ of origin; however, approximately 20% of patients will present with a tumor identified in one or more metastatic sites. In the overwhelming majority of cases, a clinical history, physical examination, laboratory tests, functional and radiographic imaging (positron emission tomography/computed tomography), and histologic assessment will disclose the primary site, enabling site-directed chemotherapy. Yet, again, in approximately 20% of cases, the primary site eludes determination, even after examination of broad panels of immunohistochemical assays. These cancers of unknown primary organ (CUP), defined as metastatic cancers whose anatomic origin is clinically not detectable even after a thorough diagnostic evaluation, represent a heterogeneous group of malignancies and account for approximately 4% of cancer diagnoses ( 1 , 2 ). Interestingly, in our experience, even after postmortem examination, 20% of CUPs, or about 1% of all cancers, are never anatomically defined. Although these cancers present as metastases and represent a spectrum of biological behavior, oncologists have stratified them into favorable (approximately 20%) and poor (approximately 80%) prognostic groups based on such factors as clinical presentation, host factors, tumor histology, number and location of metastatic sites, and their sensitivity to chemoradiation treatment ( 1–3 ). In general, patients with CUP have an overall survival of 6 to 9 months, although the favorable prognostic group may have a median survival of nearly 36 months.
- 2 May 2013
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 105 (11) , 759-761
Open AccessA Primary Approach to Cancers of Unknown Primary
Most solid tumors are diagnosed in their organ of origin; however, approximately 20% of patients will present with a tumor identified in one or more metastatic sites. In the overwhelming majority of cases, a clinical history, physical examination, laboratory tests, functional and radiographic imaging (positron emission tomography/computed tomography), and histologic assessment will disclose the primary site, enabling site-directed chemotherapy. Yet, again, in approximately 20% of cases, the primary site eludes determination, even after examination of broad panels of immunohistochemical assays. These cancers of unknown primary organ (CUP), defined as metastatic cancers whose anatomic origin is clinically not detectable even after a thorough diagnostic evaluation, represent a heterogeneous group of malignancies and account for approximately 4% of cancer diagnoses ( 1 , 2 ). Interestingly, in our experience, even after postmortem examination, 20% of CUPs, or about 1% of all cancers, are never anatomically defined. Although these cancers present as metastases and represent a spectrum of biological behavior, oncologists have stratified them into favorable (approximately 20%) and poor (approximately 80%) prognostic groups based on such factors as clinical presentation, host factors, tumor histology, number and location of metastatic sites, and their sensitivity to chemoradiation treatment ( 1–3 ). In general, patients with CUP have an overall survival of 6 to 9 months, although the favorable prognostic group may have a median survival of nearly 36 months.
- Open Access
- 25 January 2013
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 105 (5) , 368-370
Re: Age-Specific Incidence of Breast Cancer Subtypes: Understanding the Black–White Crossover
In a recent article in the Journal, Dr. Clarke and colleagues (1) presented data from the California Cancer Registry on age-specific incidence of breast cancer subtypes investigating whether a black–white breast cancer incidence crossover exists at early ages. The authors categorized the breast cancers according to molecular phenotypes of hormone receptor (HR) expression (estrogen receptor [ER] and progesterone receptor) and protein overexpression (or DNA amplification) of HER2. The stratification of the subtypes produces four informative categories: HR+/HER2−, HR+/HER2+, HR−/HER2+, and HR−/HER2− (so-called triple-negative breast cancer [TNBC]). Their white and black HR+ breast cancer cohorts included 42034 and 3350 cases, respectively (1).
- 25 January 2013
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 105 (5) , 368-370
Open AccessRe: Age-Specific Incidence of Breast Cancer Subtypes: Understanding the Black–White Crossover
In a recent article in the Journal, Dr. Clarke and colleagues (1) presented data from the California Cancer Registry on age-specific incidence of breast cancer subtypes investigating whether a black–white breast cancer incidence crossover exists at early ages. The authors categorized the breast cancers according to molecular phenotypes of hormone receptor (HR) expression (estrogen receptor [ER] and progesterone receptor) and protein overexpression (or DNA amplification) of HER2. The stratification of the subtypes produces four informative categories: HR+/HER2−, HR+/HER2+, HR−/HER2+, and HR−/HER2− (so-called triple-negative breast cancer [TNBC]). Their white and black HR+ breast cancer cohorts included 42034 and 3350 cases, respectively (1).
- 1 January 2012
- Published by Wolters Kluwer Health in Pathology Case Reviews
- Vol. 17 (5) , 207-210
Intraoperative Surgical Pathology
Intraoperative consultations guide the hand of the surgeon in identifying lesional tissue, in assessing the adequacy of resection margins, in examining lymph nodes for the mediastinal staging of nodal extent of tumor, and for the processing of selected tissue for special studies. Although there is a tendency to believe that the “frozen section” has all the answers for the intraoperative consultation, in practice, the pathologist exercises a series of analyses to come to a final or favored conclusion. A logistic odds analysis, based on the previous odds among differential diagnoses and the generation of likelihood ratios to arrive at the posterior odds, represents a helpful approach to the decision analysis. We present 2 challenging cases where decision analysis provided a successful method to arrive at a correct diagnosis in situations where the composite data were contradictory. Moreover, the approach illustrates how all the information obtained from clinical and radiographic studies, gross specimen analysis, and microscopic evaluation of cytological preparations and cryostat sections is necessary to achieve a meaningful result.
- 1 January 2012
- Published by Wolters Kluwer Health in Pathology Case Reviews
- Vol. 17 (5) , 207-210
Intraoperative Surgical Pathology
Intraoperative consultations guide the hand of the surgeon in identifying lesional tissue, in assessing the adequacy of resection margins, in examining lymph nodes for the mediastinal staging of nodal extent of tumor, and for the processing of selected tissue for special studies. Although there is a tendency to believe that the “frozen section” has all the answers for the intraoperative consultation, in practice, the pathologist exercises a series of analyses to come to a final or favored conclusion. A logistic odds analysis, based on the previous odds among differential diagnoses and the generation of likelihood ratios to arrive at the posterior odds, represents a helpful approach to the decision analysis. We present 2 challenging cases where decision analysis provided a successful method to arrive at a correct diagnosis in situations where the composite data were contradictory. Moreover, the approach illustrates how all the information obtained from clinical and radiographic studies, gross specimen analysis, and microscopic evaluation of cytological preparations and cryostat sections is necessary to achieve a meaningful result.
- 1 January 2009
- Published by Wiley in Archives of Pathology & Laboratory Medicine
- Vol. 133 (1) , 67-71
Carcinomas of the pancreas, gallbladder, extrahepatic bile ducts, and ampulla of vater share a field for carcinogenesis: a population-based study.
Carcinomas co-occur in the pancreas, extrahepatic bile ducts, and ampulla of Vater. We investigated whether cancers originating in these sites represent a field effect similar to that observed in the lung and upper aerodigestive tract. To determine whether a field effect for carcinogenesis exists in the ampulla of Vater, extrahepatic bile ducts, gallbladder, and pancreas. Data were obtained from National Cancer Institute's Surveillance Epidemiology and End Results Program from 1973 through 2005. Cases were compared by age frequency density plots, age-specific incidence rates, and logarithmic plots of the age-specific incidence rates and age of diagnosis. Incidence rates were 11.71, 1.43, 0.88, and 0.49 per 100,000 persons at risk for pancreatic, gallbladder, extrahepatic bile ducts, and ampullary carcinomas, respectively. Age frequency density plots were congruent for cancers originating in all 4 sites. Logarithmic plots of the age-specific incidence rates with age of diagnosis produced parallel linear rate patterns for the 4 sites indicative of similar populations for tumor development. However, density and logarithmic plots of pancreatic endocrine carcinomas, a tumor of different cellular differentiation and carcinogenic pathway, served as a comparison. The endocrine carcinomas showed a different age distribution and nonparallel rate patterns with ductal carcinomas. Carcinomas of the pancreas, gallbladder, extrahepatic bile ducts, and ampulla have a common embryonic cellular ancestry, differentiation pathways, mucosal histologic patterns, and population-related tumor development indicating a field effect in carcinogenesis. Parallel linear rate patterns indicate (1) the rate of cancer development is similar in all 4 sites even though the absolute incidence rates vary and (2) regardless of location, the ductal epithelium is equally susceptible to malignant transformation. If carcinogenic pathways to cancer are similar, then the different incidence rates seen clinically may depend on the relative surface area of the ductal system in these sites. Pancreatic cancers are most common because the surface area of the pancreas' ductal system is greater than that of the gallbladder, extrahepatic bile ducts, and ampulla.
- 1 January 2009
- Published by Wiley in Archives of Pathology & Laboratory Medicine
- Vol. 133 (1) , 67-71
Carcinomas of the pancreas, gallbladder, extrahepatic bile ducts, and ampulla of vater share a field for carcinogenesis: a population-based study.
Carcinomas co-occur in the pancreas, extrahepatic bile ducts, and ampulla of Vater. We investigated whether cancers originating in these sites represent a field effect similar to that observed in the lung and upper aerodigestive tract. To determine whether a field effect for carcinogenesis exists in the ampulla of Vater, extrahepatic bile ducts, gallbladder, and pancreas. Data were obtained from National Cancer Institute's Surveillance Epidemiology and End Results Program from 1973 through 2005. Cases were compared by age frequency density plots, age-specific incidence rates, and logarithmic plots of the age-specific incidence rates and age of diagnosis. Incidence rates were 11.71, 1.43, 0.88, and 0.49 per 100,000 persons at risk for pancreatic, gallbladder, extrahepatic bile ducts, and ampullary carcinomas, respectively. Age frequency density plots were congruent for cancers originating in all 4 sites. Logarithmic plots of the age-specific incidence rates with age of diagnosis produced parallel linear rate patterns for the 4 sites indicative of similar populations for tumor development. However, density and logarithmic plots of pancreatic endocrine carcinomas, a tumor of different cellular differentiation and carcinogenic pathway, served as a comparison. The endocrine carcinomas showed a different age distribution and nonparallel rate patterns with ductal carcinomas. Carcinomas of the pancreas, gallbladder, extrahepatic bile ducts, and ampulla have a common embryonic cellular ancestry, differentiation pathways, mucosal histologic patterns, and population-related tumor development indicating a field effect in carcinogenesis. Parallel linear rate patterns indicate (1) the rate of cancer development is similar in all 4 sites even though the absolute incidence rates vary and (2) regardless of location, the ductal epithelium is equally susceptible to malignant transformation. If carcinogenic pathways to cancer are similar, then the different incidence rates seen clinically may depend on the relative surface area of the ductal system in these sites. Pancreatic cancers are most common because the surface area of the pancreas' ductal system is greater than that of the gallbladder, extrahepatic bile ducts, and ampulla.